SureTrader SureTrader SureTrader
Home > Boards > US Listed > Medical - Healthcare >

Biocept, Inc. (BIOC)

Add BIOC Price Alert      Hide Sticky   Hide Intro
Search This Board:
Last Post: 1/20/2017 10:51:15 AM - Followers: 61 - Board type: Free - Posts Today: 2

Biocept, Inc., headquartered in San Diego, California, is a commercial-stage oncology diagnostics company focused on providing information on patients' tumors to physicians using its proprietary technology platform to help improve individual patient treatment. Biocept has developed proprietary technology platforms for capture and analysis of circulating tumor DNA, both in circulating tumor cells (CTCs) and in plasma (cell free tumor DNA or ctDNA). A standard blood sample is utilized to provide physicians with important prognostic and predictive information to enhance individual treatment of their patients with cancer. Biocept currently offers its OncoCEE-BRTM test for breast cancer and OncoCEE-LUTM for non-small cell lung cancer and OncoCEE- GATM for Gastric Cancer and plans to introduce additional CLIA validated tests for breast, lung, colorectal, melanoma, prostate and other solid tumors based on its proprietary technology platforms over the coming months.


The Leader in Clinical Trial Management Solutions

BioClinica accelerates the development of new medical therapies by delivering expertise and technologies that enhance clinical research, worldwide. Our industry-leading Medical Imaging services, Cardiac Safety, and enterprise eClinical platform bring a new level of quality and efficiency to every phase of clinical development. Our experience spans three decades and includes thousands of studies in all therapeutic areas, from design and management, through submission and post-approval. BioClinica serves more than 400 pharmaceutical, biotechnology, and device companies – including all the top 20 - through a network of offices in the U.S., Europe, and Asia.


IRT Sourcing Models, Breaking with Convention (Part 2)

Submitted by Steve Goldstein on February 18, 2015 - 4:34pm

What Makes an IRT Great for Technology Transfer?

In the last blog we talked about how technology transfer is gaining ground on the conventional Software as a Service (SaaS) IRT sourcing model. In this blog post, I will explain the advantages of the technology and design behind Trident that make it particularly well-suited for IRT technology transfer. So let's dive right in.

IRT Sourcing Models, Breaking with Convention (Part 1)

Submitted by Steve Goldstein on February 18, 2015 - 4:02pm

Technology Transfer Gaining on Saas

When it comes to Interactive Response Technology (IRT) – systems used to perform subject randomization, drug dispensing and study drug resupply – Software as a Service (SaaS) continues to be the conventional delivery model including here at BioClinica.

Key Insights from SCDM Euro Leadership Forum

Submitted by Jonathan Andrus on February 6, 2015 - 4:15pm

Break-out Group Dissects the Development of a Risk-Based Approach To Clinical Trial Management

As SCDM's 2014 Chair I had the honor of presenting the keynote at the EU Leadership Forum held in The Netherlands, December 2014. Celebrating the organization's 20th Anniversary and all that's been accomplished, we took a light-hearted look at the Evolution of the Clinical Data Management Role.

Escalating Role of Medical Imaging in AD Clinical Trials

Submitted by Eli Berdougo on January 30, 2015 - 1:12pm

Studies Reveal Impact of Implementing, Standardizing, and Developing Neuroimaging Endpoints in Alzheimer's Disease Trials

Alzheimer's disease is one of the most important health challenges facing aging populations worldwide. Disease modifying therapies are desperately needed and many potential treatments are currently being tested in clinical trials. The role and impact of medical imaging in AD trials continues to grow, especially as clinicians and scientists seek to define and treat AD at the earliest stages of disease.

Risk-Based Monitoring Technology: 5 Essential Capabilities

Submitted by Courtney McBean on January 27, 2015 - 2:05pm

If you've spent time researching risk-based monitoring (RBM) over the past year, you know dozens of academics, CROs, clinical trial practitioners, and statisticians have proposed varied approaches based on sponsor needs and trial designs. Unfortunately, despite an abundance of theoretical perspectives on RBM, clinical trial teams soon discover a significant gap still exists between perspectives and actual tools to enable real-world RBM implementation.

Time to Take Action and Make Risk-Based Monitoring a Reality

Submitted by Courtney McBean on January 19, 2015 - 12:23pm

Intense interest surrounding RBM shows alignment of all the right elements — technology, regulatory bodies and the industry itself – to make risk-based monitoring a reality. If implemented with the right components, this approach could result in the most efficient trial management possible.

What’s New with CDISC Standards?

Submitted by Jennifer Price on December 16, 2014 - 11:13am

Progress on CDISC Standards has come at a quickened pace in recent years. Helping make advancement of industry-wide standards possible is collaboration among CDISC and other participating organizations (Critical Path Institute, Association of Clinical Research Organizations, Innovative Medicines Initiative, and National Cancer Institute). Joining in the collaboration are regulatory authorities and the pharma industry itself, as well as TransCelerate Biopharma which continues to press forward with its standards initiative.

Evolution of the Clinical Data Management Role, 1994-2014

Submitted by Jonathan Andrus on December 9, 2014 - 12:11pm

20-Year Retrospective

The role of the Clinical Data Manager (CDM) has changed immensely since 1994, both in terms of role and function. Let's take a fun retrospective look at the great strides made in our field over these last 20 years, and more importantly, where the CDM role is headed. Let's begin with 1994, in honor of the Society of Clinical Data Management (SCDM), which commemorated its 20th Anniversary in 2014.

3 Reasons to Share Data from Unsuccessful Clinical Trials

Submitted by Eli Berdougo on November 25, 2014 - 4:53pm
3 Reasons to Share Data from Unsuccessful Clinical Trials

A recent proposal by the U.S. Department of Health and Human Services (HHS) could expand the amount of clinical trial data that drug companies must share with the public. Under the proposal, clinical trial sponsors would be required to report findings for drugs and devices that fail to reach approval.

eSource: Are You On-Trend with Other Sponsors?

Submitted by Jennifer Price on November 12, 2014 - 11:17am

eSource is a topic that has everyone talking and it continues to dominate the conversation at industry gatherings, including the annual SCDM conference held earlier this fall. From what I heard there − and continue to hear – sponsors' experience with eSource runs the full gamut.

Why 'Intelligent Monitoring' Is Even Smarter than Risk-Based Monitoring

Submitted by Courtney McBean on October 31, 2014 - 1:27pm

When I speak on the topic of risk-based monitoring (RBM) at industry events, someone invariably comes up afterward to say how nice it is we finally stopped talking about risk-based monitoring!

eSource: Still in the Shallow End of the Pool?

Submitted by Jennifer Price on October 23, 2014 - 3:25pm

Dipping a toe in the water is always easier than jumping right into something new.

I am reminded of this old axiom as I look back at the recent SCDM conference and see it holds true for eSource.

Testing different eSource modalities within a controlled environment is one way to get acclimated and explore the use of eSource in your clinical trials while building experience – all in a low-risk way. Beginning with data that's directly entered as eSource is a whole lot easier and safer than attempting to hit it 100 percent from the high dive on the first try.

7 Principles of eSource Use

Submitted by Jennifer Price on October 17, 2014 - 10:31am
7 Principles of eSource Use

As I write this, I’m on a return flight home to Philadelphia from Las Vegas where I attended the Annual SCDM conference. It was a great event and I’m pretty revved up to share what I saw and heard there, especially on the evolving topic of eSource.

One session I’d like to tell you about is an eSource roundtable that was moderated by Linda King, Director of Global Data Delivery at Eli Lilly and Demetris Zambas, VP and Global Head, Data Management at Novartis. Representatives from CDISC, Merck, J&J, AssisTek, Quintiles, and Otsuka rounded out the expert panel.

Response to TransCelerate’s Risk-Based Monitoring Paper: Technology Considerations to Enable Risk-Based Monitoring Methodology

Submitted by Courtney McBean on September 30, 2014 - 1:46pm

Have you had a chance to read the latest TransCelerate paper on risk-based monitoring (RBM)?

If not, I highly recommend getting your eyes on Technology Considerations to Enable the Risk-Based Monitoring Methodology, published online in August on behalf of the Drug Information Association (DIA). This paper serves as a tremendous resource for any organization interested in new enterprise technology to help realize the advantages of risk-based monitoring.

Highlights from the 2014 Osteoarthritis Imaging Workshop

Submitted by Eli Berdougo on September 23, 2014 - 2:58pm
Highlights from the 2014 Osteoarthritis Imaging Workshop

This summer, experts from academia, industry and regulatory sectors gathered in Reykjavik, Iceland for The International Workshop on Osteoarthritis Imaging (IWOAI) to discuss the latest advances related to imaging in Osteoarthritis (OA). Presentations at this conference centered on new imaging techniques and analytical methods for monitoring OA pathophysiology and evaluating imaging data from clinical studies.

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
BIOC News: Biocept Awarded Patent in Australia for the Use of Antibodies in Microchannels to Capture Circulating Tumor Cells and Other R... 01/19/2017 09:05:00 AM
BIOC News: Amended Statement of Ownership (sc 13g/a) 01/11/2017 03:41:56 PM
BIOC News: Biocept Secures In-Network Provider Agreement with Blue Cross Blue Shield of Texas 01/10/2017 09:36:00 AM
BIOC News: Clinical Utility of Biocept's Liquid Biopsy Platform Demonstrated in Study Results Presented at the 2016 San Antonio Breast C... 12/08/2016 08:05:00 AM
BIOC News: Biocept Presents Robust Analytical Validation Study Results for its PD-L1 Liquid Biopsy Test at the 17th IASLC World Conferen... 12/07/2016 09:45:00 AM
#1142   Showing some strength today. Maybe the heavy digiholic 01/20/17 10:51:14 AM
#1141   We'll know in the first 30 min if digiholic 01/20/17 09:14:08 AM
#1140   I was slammed last year with work and digiholic 01/19/17 04:11:44 PM
#1139   You've been around here for quite a few ArtVandalay85 01/19/17 04:02:33 PM
#1138   This needs to hit my target after hours digiholic 01/19/17 04:01:24 PM
#1137   I am hoping this gets back to 1.77 digiholic 01/19/17 12:42:47 PM
#1136   I've already sold for a loss here. I'm ArtVandalay85 01/19/17 12:29:47 PM
#1135   Whoever has been selling must have only paid digiholic 01/19/17 11:53:40 AM
#1134   I was moving my bid down and someone digiholic 01/19/17 10:29:31 AM
#1133   NAILED THE 1.55 CALL, LOD 1.56 NOW 1.72 [SMART MONEY] 01/19/17 10:16:24 AM
#1132   I better move that buy down a bit, digiholic 01/19/17 09:46:17 AM
#1131   It needs to bounce off of 1.55 so digiholic 01/19/17 09:39:19 AM
#1130   16,200 BUY @ 1.83 [SMART MONEY] 01/19/17 09:28:03 AM
#1129   Hmm, getting a little action this morning on digiholic 01/19/17 09:18:43 AM
#1128   Ha, that's what I get for selling out digiholic 01/18/17 01:20:29 PM
#1127   Rule #1: never hold a stock on vacation. What ArtVandalay85 01/18/17 12:39:41 PM
#1126   They are beating the breaks off of this digiholic 01/18/17 10:46:07 AM
#1125   analysts have optimistic trends for bioc.....jan 17 goog fin. dirtydozen911 01/18/17 09:32:06 AM
#1124   Yeah, I made so much off of it digiholic 01/17/17 03:48:01 PM
#1123   Have your answer now......many have moved on. Hawkeye_tt 01/17/17 03:14:26 PM
#1122   Pre-market is just noise. zzz digiholic 01/17/17 09:19:17 AM
#1121   Today we get to find out whether or digiholic 01/17/17 09:02:16 AM
#1120   Feeling good about tomorrow, Friday did better than Phil2016 01/16/17 10:15:57 AM
#1119   Is this a good short? Skiddmarks 01/14/17 06:57:22 PM
#1118   Got back in for some at 2.04. digiholic 01/13/17 03:57:16 PM
#1117   Someone is making the market in order to digiholic 01/13/17 02:15:39 PM
#1116   BIOC 3.3 damn PAC 01/13/17 10:42:56 AM
#1115   $3 coming soon Trons 01/13/17 10:33:37 AM
#1114   BIOC 1.95 added. Playing for bounce PAC 01/13/17 10:19:05 AM
#1113   Interesting, appreciate the info. I'm on vacation, so ArtVandalay85 01/12/17 10:44:58 PM
#1111   This was last year... mmscoutregiment 01/12/17 07:48:18 PM
#1110   It did not show up because it happened mmscoutregiment 01/12/17 07:47:10 PM
#1109   Yes, and Illinois followed second... ArtVandalay85 01/12/17 06:24:35 PM
#1108   Was Texas the first State they got BCBS The Rainmaker 01/12/17 05:08:02 PM
#1107   There was a PR Newswire regarding a deal ArtVandalay85 01/12/17 04:28:33 PM
#1106   I wonder how many other Sates besides Texas The Rainmaker 01/12/17 04:25:42 PM
#1105   Some decent consolidation today. I'd say the digiholic 01/12/17 04:10:08 PM
#1104 guchu 01/12/17 03:12:11 PM
#1103   What Wall Street is saying about Biocept, Inc. (NASDAQ:BIOC) guchu 01/12/17 03:06:19 PM
#1102   Biocept Announces In-Network Agreement with Blue Cross Blue guchu 01/12/17 02:06:36 PM
#1101   Any reason why the Illinois news is not ArtVandalay85 01/12/17 01:19:16 PM
#1100   Bummer is I had a big buy in digiholic 01/12/17 12:32:04 PM
#1099   Yeah, it's getting a little strength. Hmm digiholic 01/12/17 12:17:34 PM
#1098   BIOC $2.1falling with markets as bios getting drilled. PAC 01/12/17 12:01:34 PM
#1097   blue cross of Illinois on board.....other states will dirtydozen911 01/12/17 11:17:04 AM
#1096   Biocept Announces In-Network Agreement with Blue Cross Blue Leo001 01/12/17 11:05:45 AM
#1095   I sold all but 500 shares at close digiholic 01/12/17 10:25:20 AM
#1094   they actually cut their stake by 25%.... $bioc arigold0702 01/12/17 04:45:08 AM
#1093   This stock is the next ETRM, in the jones99 01/12/17 04:24:12 AM
#1092   Yeah. Nice close. christalball 01/12/17 04:08:02 AM